Medicare announces new payment rates for COVID-19 monoclonal antibody infusions
Effective immediately, Medicare will pay $750 to administer monoclonal antibodies to COVID-19 patients in their residence or temporary lodging and increase payment to administer them in most other care settings to $450 from $310 to better align payment with provider costs, the Centers for Medicare & Medicaid Services announced yesterday. CMS is updating its COVID-19 toolkits and coding resources to reflect the new payment rates.
Related News Articles
Headline
The AHA March 3 urged the Health Resources and Services Administration to take immediate action to stop a new Novo Nordisk policy from taking effect…
Chairperson's File
Leaders of rural hospitals face similar challenges as leaders of urban hospitals, but with an added degree of complexity, including recruiting staff,…
Headline
The Centers for Medicare & Medicaid Services Feb. 25 released a request for information on potential regulatory changes in a possible future…
Headline
The Health Resources and Services Administration Feb. 25 said it will extend the deadline to April 20 to receive comments on its request for information on…
Headline
The U.S. District Court for the District of Hawaii Feb. 23 denied a preliminary injunction requested by AstraZeneca in a case challenging the state’s law…
Headline
The Centers for Medicare & Medicaid Services Feb. 23 announced the development of its Medicare App Library. As part of the agency’s Health Technology…